Introduction
============

Germline mutations in *BRCA1*and *BRCA2*confer high risks of breast, ovarian and other cancers \[[@B1]-[@B3]\] and account for 15 to 20% of the excess familial risk of breast cancer among first degree relatives \[[@B4],[@B5]\]. Breast cancer risks for *BRCA1*and *BRCA2*mutation carriers have been estimated to range between 40 and 87% by age 70 \[[@B6]-[@B12]\] with population-based estimates tending to be lower than estimates based on families with multiple affected individuals \[[@B6],[@B8]\]. Moreover, breast cancer risks for mutation carriers were found to vary according to the age at diagnosis and the type of cancer of the index patient involved in the family ascertainment \[[@B6],[@B7],[@B11]\]. Such evidence suggests that genetic or other risk factors that cluster in families modify the cancer risks conferred by *BRCA*1 and *BRCA2*mutations.

A substantial body of work indicates that tumours arising in patients with germline *BRCA1*mutations are morphologically and genetically distinct from those arising in carriers of *BRCA2*mutations and from tumours in patients lacking mutations. In gene expression studies, *BRCA1*-associated tumours are often classified as basal subtype tumours \[[@B13],[@B14]\]. This is reflected in their higher grade, and morphologic features including lymphocytic infiltrate, pushing margins and syncytial growth. Being basal-like they express several markers that are normally expressed in the basal/myoepithelial cells of the breast, including stratified epithelial cytokeratins 5/6, 14 and 17. *BRCA1*-associated tumours are more likely to be estrogen receptor (ER), progesterone receptor (PR) and HER2 negative and to harbor mutations in the *TP53*gene than age-matched sporadic breast cancers \[[@B15],[@B16]\]. *BRCA2*-associated tumours are also predominantly high-grade invasive ductal carcinomas of no special type but they often demonstrate a luminal phenotype despite their high histologic grade \[[@B13],[@B17]\]. Adjusting for grade, *BRCA2*-associated tumours are more often ER-positive and are less likely, compared with controls, to express the basal cytokeratin CK5 or to overexpress HER2/neu protein \[[@B17]\].

Establishing the estrogen receptor status of a breast cancer (positive or negative) reflects a major subdivision in breast cancer type (at least five major sub-types are recognized) and it is becoming clear that the risk factors associated with breast cancer, both genetic and epidemiological, differ according to sub-type. Genome-wide association studies (GWAS) in breast cancer have identified several common alleles (single nucleotide polymorphisms (SNPs)) associated with an increased risk of breast cancer in the general population \[[@B18]-[@B25]\]. Many of these SNPs are associated with risk for ER-positive breast cancer, fewer have so far been associated with ER-negative breast cancer risk \[[@B26],[@B27]\].

Known risk breast cancer susceptibility alleles have been genotyped in a large series of female *BRCA1*and *BRCA2*mutation carriers assembled by the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) to evaluate their associations with risk of breast cancer for mutation carriers. Of the 12 SNPs (rs2981582 in *FGFR2*, rs3803662 in *TOX3/TNRC9*, rs889312 in *MAP3K1*, rs13281615 at 8q24, rs381798 in *LSP1*, rs13387042 at 2q35, rs4973768 in *SLC4A7/NEK10*, rs10941679 at 5p12, rs6504950 in *STXBP4/COX11*, rs999737/rs10483813 in *RAD51L1*, rs2046210 at 6q25.1 and rs11249433 at 1p11.2) investigated so far, eight were associated with breast cancer risk for *BRCA2*carriers (all but SNPs at 8q24, *RAD51L1*, 6q25.1 and *STXBP4/COX11*), whereas only three SNPs (6q25.1, *TOX3/TNRC9*and 2q35) were associated with risk for *BRCA1*mutation carriers \[[@B28]-[@B31]\]. Work from the Breast Cancer Association Consortium and subsequent studies have demonstrated differences in the associations between these susceptibility loci and tumour characteristics in the general population \[[@B27],[@B32]\]. These results suggest that the observed differences in the associations between *BRCA1*and *BRCA2*mutation carriers may reflect differences in the distribution of tumour characteristics in mutation carriers. It is currently unclear whether these polymorphisms are associated with different tumour characteristics within *BRCA1*and *BRCA2*mutation carriers.

As an adjunct to predictive testing for a high risk *BRCA1*or *BRCA2*gene mutation, more individualized risk estimates that take into account additional genetic and environmental modifiers will require a more detailed understanding of how these various risk factors interact. Understanding whether common genetic variants modify the risks of developing ER-positive or ER-negative breast cancer in *BRCA1*and *BRCA2*mutation carriers could potentially influence the clinical management of these individuals. For example, knowing that a *BRCA1*mutation carrier is more likely to develop ER-positive breast cancer (than most *BRCA1*mutation carriers), may influence the choice of management strategies, such as chemoprevention. In this study, we used data from the CIMBA consortium to evaluate the associations between the 12 common breast cancer susceptibility alleles and risk for breast cancer defined by ER and PR status.

Materials and methods
=====================

Subjects
--------

Subjects were *BRCA1*and *BRCA2*mutation carriers recruited by 36 study centres in Europe, North America and Australia (Table [1](#T1){ref-type="table"}). All carriers participated in clinical or research studies at the host institutions, which have been approved by local ethics committees (list provided in Additional file [1](#S1){ref-type="supplementary-material"}, Table S1). Each committee granted approval for access and use of the medical records for the present analyses.

###### 

Number of mutation carriers by country grouping affection status and tumour marker characteristics

  Country Group                 BRCA1    BRCA2   Unaffected   Breast Cancer   ER-     ER+     PR-     PR+
  ----------------------------- -------- ------- ------------ --------------- ------- ------- ------- -------
                                                                                                      
  Austria^1^                    465      179     318          326             76      51      76      44
  Australia^2^                  660      552     541          671             235     200     297     121
  Canada^3^                     443      358     386          415             107     70      89      68
  Denmark^4^                    507      319     463          363             98      93      79      45
  France-Belgium-Spain^5^       1,673    1,256   1,217        1,712           140     165     1,661   127
  Finland^6^                    103      105     91           117             59      54      74      39
  Germany^7^                    1,231    589     648          1,172           443     336     457     311
  Iceland^8^                    0        135     24           111             21      57      18      57
  Italy^9^                      994      666     686          974             203     251     231     216
  Latvia-Lithuania-Russia^10^   190      0       79           111             21      6       18      7
  Sweden^11^                    537      177     396          318             86      54      89      50
  Netherlands^12^               804      319     611          512             72      41      69      29
  UK-Eire^13^                   1,107    866     1,008        965             268     239     175     104
  USA^14^                       2,707    1559    2,118        2048            482     366     512     297
                                                                                                      
  Total                         11,421   7,080   8,686        9,815           2,311   1,983   2,345   1,515

Studies in country groups:1:MUV; 2:BCFR/KCONFAB; 3:OCGN/BCFR/INHERIT; 4:CBCS/OUH; 5: GEMO/CNIO/HCSC/ICO/MOD-SQUAD; 6:HEBCS; 7:GC-HBOC/DKFZ; 8:ILUH; 9:CONSIT-TEAM/IOVHBOCS/PBCS; 10: NNPIO/BFBOCC; 11: SWE-BRCA; 12: HEBON; 13:EMBRACE/UKGRFOCR; 14:FCCC/GEMO/GEORGETOWN/MAGIC/MAYO/MSKCC/NCI/OSU-CCG/UCI/UCSF/UKGRFOCR/UPENN/WCRI

The large majority of carriers were recruited through cancer genetics clinics offering genetic testing, and enrolled into national or regional studies. Eligibility to participate in CIMBA is restricted to female carriers of pathogenic *BRCA1*or *BRCA2*mutations who were 18 years old or older at recruitment. Information collected included the year of birth; mutation description, including nucleotide position and base change; age at last follow-up; ages at breast and ovarian cancer diagnoses; and age or date at bilateral prophylactic mastectomy. Information was also available on the country of residence. Related individuals were identified through a unique family identifier. Women were included in the analysis if they carried mutations that were pathogenic according to generally recognized criteria. Only studies that provided tumour pathology information and had genotype information were included in the analysis. However, to maximise the available information, genotyped mutation carriers within those studies missing information on tumour characteristics were included in the analysis and their disease subtype was assumed to be missing at random (see statistical methods for details). Further details about the CIMBA initiative can be found elsewhere \[[@B33]\].

Tumour pathology data collection
--------------------------------

Tumour pathology data were amalgamated from a range of sources, specifically patient pathology reports, medical records, pathology review data, tumour registry records and results from tissue microarrays. Estrogen and progesterone receptor status was provided as negative or positive, with supplementary immunohistochemistry scoring data and methodology provided when available. Based on definitions supplied, most centres employed a cut off of ≥10% of tumour cells stained positive to define receptor positivity. To ensure consistency across studies, when information on the proportion of cells stained was available, we used the same cut-off to define ER and PR positive tumours. For a small number of cases where composite scoring methods based on the proportion and intensity of staining were available (Allred score, Remmele score and H-score), widely-accepted cut-offs were used (Additional file [1](#S1){ref-type="supplementary-material"}, Table S2). Consistency checks were performed to validate receptor data against supplementary scoring information if provided.

Genotyping
----------

This analysis included genotype data on 12 SNPs that had been previously assessed for their associations with the overall risk of breast cancer for *BRCA1*and *BRCA2*mutation carriers in CIMBA. Genotyping was performed using either the iPLEX or Taqman platforms and has been described in detail in the previous reports \[[@B28]-[@B31]\]. To ensure genotyping consistency, all genotyping centres were required to adhere to the CIMBA genotyping quality control criteria which are described in detail online \[[@B34]\]. The 12 SNPs genotyped were rs2981582 in *FGFR2*, rs3803662 in *TOX3/TNRC9*, rs889312 in *MAP3K1*, rs3817198 in *LSP1*, rs13387042 at 2q35, rs13281615 at 8q24, rs4973768 near *SLC4A7/NEK10*, rs6504950 in the *STXBP4/COX11*region, rs2046210 near *ESR1*at 6q25.1 and rs11249433 at 1p11.2. A Taqman assay could not be adequately designed for SNP rs999737 in the *RAD51L1*region and studies using this platform genotyped the surrogate SNP rs10483813 (pair-wise r^2^= 1 with rs999737 based on HapMap CEU data). Data for these two SNPs were combined and treated as a single locus in the analysis of associations.

Statistical analysis
--------------------

The aim of this study was to evaluate the associations between each genotype and breast cancer subtypes defined by tumour characteristics in *BRCA1*and *BRCA2*mutation carriers separately. The phenotype of each individual was defined by the age at diagnosis of breast cancer and its subtype or by age at last follow-up. Individuals were censored at the age of the first breast cancer diagnosis, ovarian cancer diagnosis, or bilateral prophylactic mastectomy or the age at last observation. Mutation carriers censored at ovarian cancer diagnosis were considered unaffected.

The analysis of risk modifiers in *BRCA1*and *BRCA2*mutation carriers is complicated by the fact that mutation carriers are not randomly sampled with respect to their disease status. Many carriers are sampled through families seen in genetic clinics. The first tested individual in a family is usually someone diagnosed with cancer at a relatively young age. Such study designs, therefore, tend to lead to an over-sampling of affected individuals, and standard analytical methods like Cox regression or case-control analysis may lead to biased estimates of the risk ratios \[[@B35]\]. This can be illustrated by considering an individual affected at age *t*. In a standard analysis of a cohort study or a case-control analysis, the SNP genotype for the individual will be compared with those of all individuals at risk at age *t*or in a case-control analysis, with controls randomly sampled from all possible at risk individuals. This analysis leads to consistent estimates of the hazard ratio or odds ratio estimates. However, in the present design, mutation carriers are already selected on the basis of disease status (where affected individuals are over-sampled). If standard cohort analysis were applied to these data, it would lead to affected individuals at age *t*being compared to unaffected carriers selected on the basis of their future disease status. If the genotype is associated with the disease, the risk estimate will be biased to zero because too many affected individuals (in whom the at-risk genotype is overrepresented) are included in the comparison group. Simulation studies have shown that this effect can be quite marked \[[@B35]\]. To address this, a retrospective likelihood approach was previously proposed, which models the observed genotypes conditional on the disease phenotypes \[[@B36]\]. For the current analyses we have extended this method to model the simultaneous effect of each SNP on more than one tumour subtype. We briefly describe this method for the analysis of associations with ER-positive and ER-negative breast cancer, but the same principles apply for the analysis of associations with other tumour characteristics.

We modelled the likelihood of the observed genotypes and tumour subtype conditional on the disease status, that is:

$$\prod\limits_{i = 1}^{n}P\left( g_{i},d_{i} \middle| y\left( t_{i} \right) \right) = \prod\limits_{i}^{n}\frac{P\left( \left( y\left( t_{i} \right),d_{i} \middle| g_{i} \right) \right)P\left( g_{i} \right)}{P\left( {y\left( t_{i} \right)} \right)}$$

Where *y*(*t~i~*) is the disease phenotype for individual *i*at censoring age *t~i~*(breast cancer at age *t~i~*or unaffected at age *t~i~*), *d~i~*is the ER status (0 = negative, 1 = positive) and *g~i~*the observed genotype of individual *i*(*g~i~*= 0, 1 or 2 minor alleles) and *n*the number of subjects in the analysis. To allow for tumour characteristics we assumed that breast cancer consists of different disease subtypes, such that the total breast cancer incidence at age *t~i~*, *λ*(*t~i~*), is the sum of the disease incidence for the subtypes, that is *λ*(*t~i~*) = *v*(*t~i~*) + *μ*(*t~i~*), where *v*(*t~i~*) is the incidence for ER-negative disease and *μ*(*t~i~*) is the incidence of ER-positive disease. We assumed that the subtype-specific incidences depend on the underlying genotype through a Cox-proportional hazards model: $\nu\left( t_{i} \right) = \nu_{0}\left( t_{i} \right)\exp\left( {\beta^{t}\mathbf{z}_{g_{i}}} \right)$ and $\mu\left( t_{i} \right) = \mu_{0}\left( t_{i} \right)\exp\left( {\gamma^{t}\mathbf{z}_{g_{i}}} \right)$where *v*~0~(*t~i~*) and *μ*~0~(*t~i~*) and are the baseline incidences for disease subtypes (ER-negative and ER-positive respectively), $\mathbf{z}_{g_{i}}$is the genotype vector for individual *i*and ***β***and ***γ***are the subtype specific genotype log-risk ratios (for ER-negative and ER-positive breast cancer respectively). The probabilities of developing ER-positive and ER-negative breast cancer conditional on the underlying genotype were assumed to be independent. We further assumed that, if tumour subtype is unknown, the information is missing at random with respect to genotype. Then for each individual:

$$P\left( \left( y\left( t_{i} \right),d_{i} \middle| g_{i} \right) \right) = \begin{matrix}
\begin{matrix}
{= \left( {\nu_{0}\left( t_{i} \right)\exp\left( {\beta^{t}\mathbf{z}_{g_{i}}} \right)} \right)^{O_{i}{({1 - d_{i}})}} \times \left( {\mu_{0}\left( t_{i} \right)\exp\left( {\gamma^{t}\mathbf{z}_{g_{i}}} \right)} \right)^{O_{i}d_{i}} \times} \\
{\exp\left( {- \sum\limits_{u = 0}^{t_{i} - 1}\left( {\mu_{0}\left( u \right)\exp\left( {\gamma^{t}\mathbf{z}_{g_{i}}} \right) + \nu_{0}\left( u \right)\exp\left( {\beta^{t}\mathbf{z}_{g_{i}}} \right)} \right)} \right)\textsf{~if~}d_{i} = 0,\textsf{~1~}} \\
 \\
\end{matrix} \\
 \\
\begin{matrix}
{\textsf{~} = \left( {\mu_{0}\left( t_{i} \right)\exp\left( {\gamma^{t}\mathbf{z}_{g_{i}}} \right) + \nu_{0}\left( t \right)\exp\left( {\beta^{t}\mathbf{z}_{g_{i}}} \right)} \right)^{O_{i}} \times} \\
{\exp\left( {- \sum\limits_{u = 0}^{t_{i} - 1}\left( {\mu_{0}\left( u \right)\exp\left( {\gamma^{t}\mathbf{z}_{g_{i}}} \right) + \nu_{0}\left( u \right)\exp\left( {\beta^{t}\mathbf{z}_{g_{i}}} \right)} \right)} \right)\textsf{~if~}d_{i} = \textsf{~unknown}} \\
 \\
\end{matrix} \\
 \\
\end{matrix}$$

were *O~i~*= 0 if unaffected and *O~i~*= 1 if affected. Thus, the above formulation allows use of all mutation carriers irrespective of whether the tumour subtype is observed or not. The baseline incidences for each disease subtype (*v~0~*(*t~i~*) and *μ*~0~(*t~i~*)) are unknown. However, it is possible to solve for those recursively by constraining the overall breast cancer incidence for mutation carriers *λ*(*t*), to agree with external estimates as previously demonstrated \[[@B37],[@B38]\] and by imposing a further constraint on the ratio of the observed ER-positive to ER-negative breast cancers in each age group:

The likelihood in equation 1 can then be maximised jointly over the log-risk ratios ***β***and ***γ***, genotype frequencies *P(g)*and the age and subtype-specific frequencies *π*~+~(*t*) and *π*~-~(*t*) This likelihood is based on the assumption that the ascertainment of mutation carriers is dependent on the overall disease phenotype (breast cancer) but not on tumour subtypes. This allows the subtype frequencies *π*~+~(*t*) and *π~-~*(*t*) to be estimated within the dataset. Relaxing this assumption and conditioning also on tumour subtype requires external estimates for the age and subtype-specific frequencies *π*~+~(*t*) and *π*~-~(*t*).

The effect of each SNP was modelled either as a per-allele HR (multiplicative model) or as separate HRs for heterozygotes and homozygotes, and these were estimated on the logarithmic scale. Heterogeneity in the hazard ratios between tumour subtypes was examined by fitting models where *v*(*t~i~*) = *v*~0~(*t~i~*) exp (*β*~1*g*~) and *μ*(*t~i~*) = *μ*~0~(*t~i~*) exp (*β*~1~+ *β*~2~)*g*) with g = 0,1 and 2 (for 0, 1, 2 copies of the minor allele respectively) and testing for *β*~2~= 0. Analyses were carried out with the pedigree-analysis software MENDEL \[[@B39]\]. All analyses were stratified by country of residence and used calendar-year- and cohort-specific cancer incidences for *BRCA1*and *BRCA2*\[[@B40]\]. For this purpose, a stratified version of the retrospective likelihood (equation 1) was derived as described previously \[[@B36]\]. Countries with small numbers of mutation carriers were grouped together. We used a robust variance-estimation approach to allow for the non-independence among related mutation carriers \[[@B41]\].

Predicted breast cancer risks by ER status
------------------------------------------

Based on our results we computed the predicted absolute risk of developing ER-negative and ER-positive breast cancer for *BRCA1*and *BRCA2*mutation carriers by the combined 12 SNP profile. For each individual we derived an empirical score, based on the per-allele log-relative hazard estimates for each genotype, which was of the form $\sum\limits_{j = 1}^{12}\beta_{j}g_{j}$where *β~j~*is the per-allele log-hazard estimate for locus j and *g~j~*is the genotype at the same locus (taking values 0, 1 and 2). This assumes a multiplicative model for the combined SNP associations. This is a reasonable assumption given that previous analyses found no evidence of departure from the multiplicative model \[[@B35]\]. Scores were calculated for ER-positive and ER-negative disease, separately for *BRCA1*and *BRCA2*mutation carriers. The empirical distribution of the derived score was then used to compute the subtype specific incidence associated with each multilocus genotype as described previously \[[@B31]\]. We reported the absolute risks of developing ER-specific breast cancer at the 5^th^, 50^th^and 95^th^percentiles of the empirical distribution of the SNP profile.

Results
=======

A total of 11,421 *BRCA1*and 7,080 *BRCA2*mutation carriers from 36 studies had been successfully genotyped for at least one of the12 SNPs and were eligible for inclusion in these analyses. 9,815 *BRCA1*and *BRCA2*mutation carriers were censored at a first invasive breast cancer diagnosis, of whom 4,310 had information on either ER or PR (Table [1](#T1){ref-type="table"}).

Associations with ER status - BRCA1 mutation carriers
-----------------------------------------------------

There were significant differences in the HR for ER-positive and ER-negative disease for *BRCA1*mutation carriers for two SNPs (Table [2](#T2){ref-type="table"}). The *FGFR2*SNP rs2981582 exhibited the clearest difference with a strong association for ER-positive disease but not ER-negative disease (per allele HR = 1.35, 95% CI: 1.17 to 1.56, for ER-positive compared with HR = 0.91, 95% CI: 0.85 to 0.98 for ER-negative, *P*-heterogeneity = 6.5 × 10^-6^). The *SLC4A7/NEK10*SNP rs4973768 also exhibited a similar pattern (ER-positive: per-allele HR = 1.17, 95% CI: 1.03 to 1.133, compared with ER-negative: per-allele HR = 0.99, 95% CI: 0.93 to 1.06, *P*-heterogeneity = 0.027). Although there was no significant evidence of differences between the HRs for ER-positive and ER-negative breast cancer, the *TOX3/TNRC9*SNP rs3803662 was significantly associated with the risk of ER-positive disease (per-allele HR = 1.25, 95% CI: 1.06 to .46, *P*-trend = 0.0062) but not with risk for ER-negative breast cancer (per-allele HR = 1.05, 95% CI: 0.97 to 1.13, *P*-trend = 0.21). *LSP1*SNP rs3817198 was associated with the risk of ER-negative breast cancer (per-allele HR = 1.07, 95% CI: 1.00 to 1.07, *P*-trend = 0.047) but not with risk of ER-positive breast cancer (per-allele HR = 1.07, 95% CI: 0.93 to 1.22, *P*-trend = 0.33, *P*-het = 0.98). The 6q25.1 SNP rs2046210 near *ESR1*was associated with the risk for both ER-negative (per-allele HR = 1.19, 95% CI: 1.11 to 1.27, *P*-trend = 2.4 × 10^-7^) and ER-positive (per-allele HR = 1.14, 95% CI: 1.01 to 1.30, *P*-trend = 0.043) breast cancer. There was no significant evidence of association with either ER-negative or ER-positive breast cancer for any of the other SNPs, although the HR estimates tended to be higher for ER-positive breast cancer (for example, SNPs rs13387042 at 2q35 and rs13281615 at 8q24).

###### 

Genotype and per-allele hazard ratio estimates by estrogen receptor status for *BRCA1*mutation carriers

  Genotype                             **Unaffected**,   Affected by subtype, N (%)   ER-          ER+             *P*-het                                                                                         
  ------------------------------------ ----------------- ---------------------------- ------------ --------------- ---------- ------------------ ------------------ ---------- ------------------ ---------------- -----------------
  *FGFR2 rs2981582*                                                                                                                                                                                                
  GG                                   1301 (36.2)       447 (40.0)                   104 (29.6)   869 (35.1)      **1.00**                                         **1.00**                                       
  GA                                   1,721 (47.9)      516 (46.2)                   166 (47.3)   1190 (48.1)     **0.93**   **0.83 to 1.03**                      **1.24**   **0.98 to 1.57**                    
  AA                                   573 (15.9)        154 (13.8)                   81 (23.1)    416 (16.8)      **0.82**   **0.70 to 0.96**                      **1.85**   **1.40 to 2.44**                    
  Per-allele                                                                                                       **0.91**   **0.85 to 0.98**   **0.01**           **1.35**   **1.17 to 1.56**   **4 × 10^-5^**   **6.5 ×10^-6^**
  *TOX3/TNRC9 rs3803662*                                                                                                                                                                                           
  CC                                   1,811 (52.0)      545 (49.5)                   154 (45.7)   1195 (50.2)     1.00                                             **1.00**                                       
  CT                                   1,405 (40.3)      461 (41.8)                   143 (42.4)   987 (41.5)      1.06       0.96 to 1.18                          **1.20**   **0.97 to 1.50**                    
  TT                                   269 (7.7)         96 (8.7)                     40 (11.9)    199 (8.4)       1.09       0.90 to 1.31                          **1.61**   **1.14 to 2.27**                    
  Per-allele                                                                                                       1.05       0.97 to 1.13       0.21               **1.25**   **1.06 to 1.46**   **0.0062**       0.07
  *MAP3K1*rs889312                                                                                                                                                                                                 
  AA                                   1,858 (49.6)      569 (49.7)                   186 (52.1)   1319 (51.6)     1.00                                             1.00                                           
  AC                                   1,552 (41.4)      480 (41.9)                   136 (38.1)   987 (38.6)      0.97       0.87 to 1.07                          0.86       0.69 to 1.06                        
  CC                                   336 (9.0)         97 (8.5)                     35 (9.8)     250 (9.8)       0.97       0.81 to 1.16                          0.97       0.69 to 1.35                        
  Per-allele                                                                                                       0.98       0.91 to 1.06       0.56               0.97       0.83 to 1.13       0.69             0.92
  *LSP1*rs3817198                                                                                                                                                                                                  
  TT                                   1,894 (47.4)      652 (45.4)                   195 (44.5)   1205 (43.7)     1.00                                             1.00                                           
  TC                                   1,680 (42.0)      629 (43.8)                   197 (45.0)   1239 (44.9)     1.09       0.99 to 1.20                          1.11       0.92 to 1.35                        
  CC                                   422 (10.6)        154 (10.7)                   46 (10.5)    315 (11.4)      1.13       0.97 to 1.33                          1.10       0.80 to 1.50                        
  Per-allele                                                                                                       **1.07**   **1.00 to 1.15**   **0.047**          1.07       0.93 to 1.22       0.33             0.98
  2q35 rs13387042                                                                                                                                                                                                  
  GG                                   924 (24.0)        301 (22.1)                   93 (22.2)    576 (21.4)      1.00                                             1.00                                           
  GA                                   1,855 (48.3)      723 (53.1)                   194 (46.3)   1370 (50.9)     **1.17**   **1.04 to 1.32**                      1.02       0.81 to 1.30                        
  AA                                   1,064 (27.7)      338 (24.8)                   132 (31.5)   745 (27.7)      0.96       0.84 to 1.11                          1.25       0.97 to 1.62                        
  Per-allele                                                                                                       0.98       0.91 to 1.04       0.48               1.13       0.99 to 1.28       0.075            0.065
  8q24 rs13281615                                                                                                                                                                                                  
  AA                                   1,319 (32.8)      502 (35.9)                   143 (33.7)   897 (32.5)      1.00                                             1.0                                            
  AG                                   2,008 (50.0)      657 (47.0)                   198 (46.7)   1,364 (49.5)    0.98       0.88 to 1.08                          0.97       0.79 to 1.19                        
  GG                                   691 (17.9)        238 (17.0)                   83 (19.6)    496 (18.0)      1.00       0.87 to 1.16                          1.17       0.89 to 1.53                        
  Per-allele                                                                                                       1.00       0.93 to 1.07       0.93               1.06       0.93 to 1.22       0.38             0.43
  SLC4A7/NEK10 rs4973768                                                                                                                                                                                           
  CC                                   1,148 (26.2)      406 (27.2)                   103 (22.2)   691 (24.7)      1.00                                             1.00                                           
  CT                                   2,205 (50.4)      736 (49.3)                   235 (50.5)   1,399 (50.1)    0.98       0.88 to 1.08                          1.20       0.96 to 1.51                        
  TT                                   1,024 (23.4)      350 (23.5)                   127 (27.3)   703 (25.2)      0.99       0.87 to 1.12                          **1.38**   **1.07 to 1.77**                    
  Per-allele                                                                                                       0.99       0.93 to 1.06       0.83               **1.17**   **1.03 to 1.33**   **0.013**        **0.027**
  STXBP4/COX11 rs6504950                                                                                                                                                                                           
  GG                                   2,346 (53.1)      814 (53.2)                   252 (52.9)   1,502 (53.1))   1.00                                             1.00                                           
  GA                                   1,737 (39.3)      593 (37.8)                   191 (40.1)   1,127 (39.8)    1.00       0.91 to 1.10                          1.03       0.86 to 1.24                        
  AA                                   333 (7.5)         122 (8.0)                    33 (6.9)     200 (7.1)       1.04       0.88 to 1.23                          0.94       0.65 to 1.34                        
  Per-allele                                                                                                       1.01       0.94 to 1.09       0.77               1.00       0.87 to 1.15       0.97             0.87
  5p12 rs10941679                                                                                                                                                                                                  
  AA                                   2,211 (55.8)      815 (57.3)                   271 (61.0)   1,529 (56.5)    1.00                                             1.00                                           
  AG                                   1,472 (37.1)      517 (36.4)                   145 (32.7)   1,001 (37.0)    0.99       0.90 to 1.09                          0.84       0.69 to 1.02                        
  GG                                   280 (7.1)         90 (6.3)                     28 (6.3)     177 (6.5)       0.89       0.73 to 1.08                          0.84       0.58 to 1.20                        
  Per-allele                                                                                                       0.97       0.90 to 1.04       0.39               0.88       0.75 to 1.02       0.08             0.26
  6q25.1 - rs2046210                                                                                                                                                                                               
  CC                                   1,886 (43.3)      567 (38.2)                   158 (36.0)   1,007 (37.0)    **1.00**                                         **1.00**                                       
  TC                                   1,919 (44.1)      718 (48.3)                   232 (52.9)   1,305 (48.0)    **1.21**   **1.10 to 1.33**                      **1.37**   **1.13 to 1.67**                    
  TT                                   547 (12.6)        201 (13.5)                   49 (11.2)    409 (15.0)      **1.39**   **1.21 to 1.59**                      **1.11**   **0.81 to 1.53**                    
  Per-allele                                                                                                       **1.19**   **1.11 to 1.27**   **2.4 × 10^-7^**   **1.14**   **1.01 to 1.30**   **0.043**        0.60
  1p11.2 - rs11249433                                                                                                                                                                                              
  TT                                   1,491 (34.1)      506 (33.7)                   144 (32.4)   973 (35.1)      1.00                                             1.00                                           
  CT                                   2,133 (48.7)      745 (49.7)                   245 (55.2)   1,342 (48.5)    0.97       0.88 to 1.07                          1.10       0.90 to 1.34                        
  CC                                   752 (17.2)        248 (16.5)                   55 (12.4)    455 (16.4)      0.99       0.87 to 1.13                          0.76       0.56 to 1.03                        
  Per-allele                                                                                                       0.99       0.93 to 1.06       0.79               0.92       0.81 to 1.05       0.22             0.35
  ***RAD51L1*- rs999737/rs10483813**                                                                                                                                                                               
  CC/TT                                2,335 (61.5)      760 (64.1)                   212 (62.5)   1,551 (62.5)    1.00                                             1.00                                           
  TC/AT                                1,294 (34.1)      370 (31.2)                   113 (33.3)   819 (33.0)      0.92       0.83 to 1.03                          1.00       0.80 to 1.24                        
  TT/AA                                170 (4.5)         56 (4.7)                     14 (4.1)     110 (4.4)       1.02       0.81 to 1.28                          0.93       0.56 to 1.56                        
  per allele                                                                                                       0.96       0.88 to 1.04       0.34               0.98       0.82 to 1.18       0.87             0.81

*P*-het, Heterogeneity *P*-value; ER-, estrogen receptor negative; ER+, estrogen receptor positive

Associations with ER status - BRCA2 mutation carriers
-----------------------------------------------------

Only SNP rs2046210 at 6q25.1 exhibited differential associations between ER-positive and ER-negative breast cancer for *BRCA2*mutation carriers (*P*-heterogeneity = 0.045, Table [3](#T3){ref-type="table"}). The per-allele HR for ER-negative disease was estimated to be 1.17 (95% CI: 0.99 to 1.38) whereas the per-allele HR for ER-positive breast cancer was 0.97 (95% CI: 0.89 to 1.05). Although there were no significant differences in the associations between the two types of disease for *BRCA2*mutation carriers, the HR estimates for ER-positive disease tended to be larger compared to ER-negative breast cancer. SNPs at/near *FGFR2, TOX3/TNRC9, MAP3K1, LSP1*, 2q35*, SLC4A7/NEK10*, 5p12 and 1p11.2 were associated with ER-positive breast cancer for *BRCA2*mutation carriers (using either a per-allele or 2 df genotype test). The strongest associations were for the *FGFR2*rs2981582 SNP (HR for ER-positive breast cancer = 1.35, 95% CI: 1.23 to 1.48, *P*-trend = 1.4 × 10^-10^) and *TOX3/TNRC9*SNP rs3803662 (HR for ER-positive breast cancer = 1.28. 95% CI: 1.16 to 1.41, *P*-trend = 1.5 × 10^-6^). Only SNPs at or near *MAP3K1, STXBP4/COX11*and 6q25.1 were associated with the risk of ER-negative breast cancer for *BRCA2*mutation carriers.

###### 

Genotype and per-allele hazard ratio estimates by estrogen receptor status for *BRCA2*mutation carriers

  Genotype                             **Unaffected**,   Affected by subtype, N (%)   ER-          ER+          *P*-het                                                                                         
  ------------------------------------ ----------------- ---------------------------- ------------ ------------ -------------- ------------------ ----------- ---------- ------------------ ------------------- -----------
  *FGFR2 rs2981582*                                                                                                                                                                                             
  GG                                   794 (37.8)        86 (32.7)                    248 (29.5)   457 (29.8)   1.00                                          **1.00**                                          
  GA                                   987 (47.0)        137 (52.1)                   419 (49.8)   755 (49.3)   1.28           0.99 to 1.67                   **1.35**   **1.17 to 1.55**                       
  AA                                   321 (15.3)        40 (15.2)                    174 (20.7)   320 (20.9)   1.23           0.85 to 1.78                   **1.81**   **1.51 to 2.18**                       
  Per-allele                                                                                                    1.14           0.97 to 1.35       0.12        **1.35**   **1.23 to 1.48**   **1.4 × 10^-10^**   0.097
  *TOX3/TNRC9 rs3803662*                                                                                                                                                                                        
  CC                                   1,088 (53.4)      136 (53.3)                   377 (46.3)   702 (48.2)   1.00                                          **1.00**                                          
  CT                                   792 (38.9)        96 (37.7)                    361 (44.3)   604 (41.5)   0.98           0.75 to 1.27                   **1.33**   **1.17 to 1.53**                       
  TT                                   157 (7.7)         23 (9.0)                     77 (9.5)     150 (10.3)   1.27           0.83 to 1.93                   **1.54**   **1.22 to 1.95**                       
  Per-allele                                                                                                    1.06           0.88 to 1.29       0.53        **1.28**   **1.16 to 1.41**   **1.5 × 10^-6^**    0.11
  *MAP3K1*rs889312                                                                                                                                                                                              
  AA                                   1,107 (51.1)      121 (45.7)                   430 (50.3)   746 (47.7)   1.00                                          1.00                                              
  AC                                   888 (41.0)        120 (45.3)                   349 (40.8)   646 (41.3)   1.23           0.96 to 1.59                   1.03       0.90 to 1.17                           
  CC                                   170 (7.9)         24 (9.1)                     76 (8.9)     172 (11.0)   1.42           0.93 to 2.16                   **1.29**   **1.03 to 1.62**                       
  Per-allele                                                                                                    **1.21**       **1.01 to 1.45**   **0.039**   1.09       0.99 to 1.21       0.08                0.35
  *LSP1*rs3817198                                                                                                                                                                                               
  TT                                   1,075 (46.1)      142 (44.4)                   429 (42.0)   718 (42.7)   1.00                                          **1.00**                                          
  TC                                   1,005 (43.1)      146 (45.6)                   466 (45.6)   759 (45.2)   1.08           0.86 to 1.36                   **1.14**   **1.01 to 1.29**                       
  CC                                   252 (10.8)        32 (10.0)                    127 (12.4)   203 (12.1)   1.02           0.68 to 1.51                   **1.39**   **1.14 to 1.70**                       
  Per-allele                                                                                                    1.03           0.87 to 1.22       0.70        **1.17**   **1.07 to 1.28**   **5.5 × 10^-4^**    0.20
  2q35 rs13387042                                                                                                                                                                                               
  GG                                   571 (25.3)        71 (23.0)                    216 (22.0)   382 (23.1)   1.00                                          1.00                                              
  GA                                   1,080 (47.8)      156 (50.5)                   500 (50.8)   809 (48.8)   1.12           0.85 to 1.47                   **1.18**   **1.01 to 1.36**                       
  AA                                   608 (26.9)        82 (26.5)                    268 (27.2)   466 (28.1)   1.06           0.78 to 1.45                   1.13       0.95 to 1.34                           
  Per-allele                                                                                                    1.03           0.87 to 1.19       0.71        1.06       0.97 to 1.15       0.20                0.75
  8q24 rs13281615                                                                                                                                                                                               
  AA                                   794 (34.1)        99 (31.6)                    317 (31.7)   524 (31.3)   1.00                                          1.00                                              
  AG                                   1,156 (49.6)      165 (52.7)                   511 (51.1)   837 (49.9)   1.08           0.85 to 1.38                   1.05       0.92 to 1.21                           
  GG                                   382 (16.4)        49 (15.7)                    172 (17.2)   315 (18.8)   1.05           0.75 to 1.46                   1.13       0.94 to 1.35                           
  Per-allele                                                                                                    1.04           0.89 to 1.21       0.66        1.06       0.97 to 1.16       0.19                0.80
  SLC4A7/NEK10 rs4973768                                                                                                                                                                                        
  CC                                   669 (26.5)        82 (24.9)                    251 (22.6)   401 (23.5)   1.00                                          **1.00**                                          
  CT                                   1,241 (49.1)      164 (49.9)                   546 (49.4)   829 (48.7)   1.05           0.81 to 1.36                   **1.14**   **0.99 to 1.31**                       
  TT                                   618 (24.5)        83 (25.2)                    311 (28.0)   474 (27.8)   1.04           0.77 to 1.41                   **1.27**   **1.08 to 1.50**                       
  Per-allele                                                                                                    1.02           0.88 to 1.19       0.78        **1.13**   **1.04 to 1.22**   **0.0043**          0.25
  STXBP4/COX11 rs6504950                                                                                                                                                                                        
  GG                                   1,420 (55.6)      171 (51.0)                   601 (53.1)   896 (52.5)   1.00                                          1.00                                              
  GA                                   951 (37.2)        145 (43.3)                   444 (39.3)   684 (40.1)   **1.27**       **1.03 to 1.58**               1.09       0.97 to 1.23                           
  AA                                   184 (7.2)         19 (5.7)                     86 (7.6)     127 (7.4)    0.84           0.54 to 1.30                   1.08       0.87 to 1.34                           
  Per-allele                                                                                                    1.07           0.92 to 1.25       0.36        1.06       0.97 to 1.16       0.19                0.91
  5p12 rs10941679                                                                                                                                                                                               
  AA                                   1,372 (58.6)      176 (54.8)                   584 (54.8)   924 (56.3)   1.00                                          1.00                                              
  AG                                   824 (35.2)        122 (38.0)                   425 (39.9)   622 (37.9)   1.08           0.86 to 1.37                   **1.15**   **1.01 to 1.30**                       
  GG                                   146 (6.2)         23 (7.2)                     57 (5.4)     94 (5.7)     1.25           0.82 to 1.91                   0.94       0.73 to 1.22                           
  Per-allele                                                                                                    1.10           0.92 to 1.31       0.28        1.06       0.96 to 1.17       0.23                0.70
  6q25.1 - rs2046210                                                                                                                                                                                            
  CC                                   985 (39.8)        121 (39.2)                   466 (42.1)   634 (37.7)   **1.00**                                      1.00                                              
  TC                                   1,165 (47.1)      132 (42.7)                   499 (45.1)   802 (47.7)   **0.99**       **0.78 to 1.12**               0.96       0.85 to 1.08                           
  TT                                   324 (13.1)        56 (18.1)                    141 (12.8)   247 (14.7)   **1.47**       **1.08 to 2.01**               0.94       0.78 to 1.12                           
  Per-allele                                                                                                    1.17           0.99 to 1.38       0.059       0.97       0.89 to 1.05       0.41                **0.045**
  1p11.2 - rs11249433                                                                                                                                                                                           
  TT                                   895 (35.9)        107 (33.6)                   345 (31.4)   599 (34.7)   1.00                                          **1.00**                                          
  CT                                   1,226 (49.2)      160 (50.3)                   553 (50.3)   843 (48.9)   1.00           0.79 to 1.28                   **1.08**   **0.96 to 1.23**                       
  CC                                   371 (14.9)        51 (16.0)                    202 (18.4)   282 (16.4)   1.00           0.73 to 1.40                   **1.27**   **1.08 to 1.50**                       
  Per-allele                                                                                                    1.00           0.86 to 1.17       0.98        **1.12**   **1.03 to 1.22**   **0.0065**          0.23
  ***RAD51L1*- rs999737/rs10483813**                                                                                                                                                                            
  *BRCA1*                              CC/TT             1,368 (59.5)                 167 (59.0)   589 (61.4)   1,000 (62.0)   1.00                                      1.00                                   
  TC/AT                                789 (34.3)        104 (36.8)                   323 (33.6)   534 (33.1)   1.06           0.84 to 1.35                   0.94       0.83 to 1.07                           
  TT/AA                                141 (6.1)         12 (4.2)                     48 (5.0)     80 (4.9)     0.74           0.42 to 1.32                   0.87       0.67 to 1.14                           
  Per-allele                                                                                                    0.97           0.80 to 1.17       0.73        0.94       0.85 to 1.03       0.20                0.77

*P*-het, Heterogeneity *P*-value; ER-, estrogen receptor negative; ER+, estrogen receptor positive

Associations with PR status - BRCA1 mutation carriers
-----------------------------------------------------

The general pattern of associations with PR-positive and PR-negative breast cancer for *BRCA1*mutation carriers (Additional file [1](#S1){ref-type="supplementary-material"}, Table S3) was similar to that seen for ER status. Significant differences in the associations between PR-positive and PR-negative breast cancer were observed for three SNPs. The minor allele of *FGFR2*SNP rs2981582 was associated with a significantly higher risk for PR-positive breast cancer for *BRCA1*mutation carriers (per-allele HR for PR-positive = 1.29, 95% CI: 1.10 to 1.51, HR for PR-negative = 0.93, 95% CI: 0.87 to 1.00, P-heterogeneity = 7 × 10^-4^). Allele \"A\" of SNP rs13387042 at 2q35 was associated with a significantly higher risk of PR-positive breast cancer for *BRCA1*mutation carriers (HR for PR-positive breast cancer = 1.16, 95% CI: 1.01 to 1.33; HR for PR-negative = 0.97, 95% CI: 0.91 to 1.04, *P*-heterogeneity = 0.034). Although the *RAD51L1*SNP showed no differential associations with ER-status, there was evidence that the minor allele of this SNP was associated with a lower risk of PR-positive breast cancer (HR for PR-positive = 0.79, 95% CI: 0.61 to 0.95; HR for PR-negative = 1.02, 95% CI: 0.94 to 1.11; *P*-heterogeneity = 0.027). The only SNPs associated with risk for PR-negative breast cancer were SNPs at 6q25.1 (per-allele HR = 1.19, 95% CI: 1.11 to 1.27, *P*-trend = 3.7 × 10^-7^), and in *LSP1*(per-allele HR = 1.09, 95% CI: 1.01 to 1.16, *P*-trend = 0.017), but these were not significantly different from the associations with PR-positive breast cancer for *BRCA1*mutation carriers.

Associations with PR status - BRCA2 mutation carriers
-----------------------------------------------------

Only two SNPs demonstrated significant differences in the associations with PR-positive and PR-negative breast cancer for *BRCA2*mutation carriers (Additional file [1](#S1){ref-type="supplementary-material"}, Table S4). SNP rs13387042 at 2q35 was associated with a higher risk of PR-positive breast cancer (per-allele HR for PR-positive = 1.14, 95% CI: 1.03 to 1.25; per-allele HR for PR-negative = 0.92, 95% CI: 0.81 to 1.04, *P*-heterogeneity = 0.009). SNP rs10941679 at 5p12 was also associated with a higher risk of PR-positive breast cancer for *BRCA2*mutation carriers (per-allele HR for PR-positive = 1.15. 95% CI: 1.03 to 1.27, HR for PR-negative = 0.94, 95% CI: 0.81 to 1.09, *P*-heterogeneity = 0.028). SNPs near or at *FGFR2, TOX3/TNRC9, LSP1*were associated with both PR-negative and PR-positive breast cancer, whereas the 1p11.2 SNP was associated with risk for PR-negative breast cancer. *MAP3K1*and *SLC4A7/NEK10*were associated only with risk of PR-positive breast cancer among *BRCA2*mutation carriers.

Absolute risks of developing ER-positive and ER-negative breast cancer by SNP profile
-------------------------------------------------------------------------------------

Using the estimated HRs for ER-positive and ER-negative breast cancer for *BRCA1*and *BRCA2*mutation carriers, we computed the predicted absolute risk of developing ER-negative and ER-positive breast cancer at various percentiles of the combined SNP distribution. The SNP profile distribution is different for each disease subtype and mutation. We note that SNPs for which the per-allele HR estimates are close to 1.0 contribute little to the predicted ER-specific risks. Figure [1](#F1){ref-type="fig"} shows the predicted risks of developing ER-negative and ER-positive breast cancer for *BRCA1*and *BRCA2*mutation carriers at the 5^th^, 50^th^and 95^th^percentiles of the empirical risk distribution of the combined SNP profile. A *BRCA1*mutation carrier at the 5^th^percentile of the SNP profile distribution would be at 43% risk of developing ER-negative breast cancer by age 80 compared with 60% for *BRCA1*mutation carriers at the 95^th^percentile of the risk distribution. The risks of developing ER-positive breast cancer would be 18% and 46% by age 80 at the 5^th^and 95^th^percentiles of the ER-positive breast cancer risk distribution. *BRCA2*mutation carriers at the 5^th^percentile of the ER-negative breast cancer risk distribution are predicted to have a 22% risk of developing ER-negative breast cancer by age 80 compared with 39% for the 95^th^percentile of the risk distribution. The risks of developing ER-positive breast cancer by age 80 for *BRCA2*carriers varied from 33% to 70% at the 5^th^and 95^th^percentiles of the ER-positive risk distribution respectively.

![**Predicted risks of developing ER-negative and ER-positive breast cancer based on SNP profiles**. Solid lines depict the median risks and dotted lines the risks at the 5^th^and 95^th^percentiles of the risk distribution. The absolute risk differences between individuals at the extremes of the risk distributions are greater for ER-positive breast cancer.](bcr3052-1){#F1}

Discussion
==========

This is the first report to investigate the associations between 12 common breast cancer susceptibility alleles and ER and PR status of breast tumours in *BRCA1*and *BRCA2*mutation carriers. The analysis was made possible by the availability of a large, combined dataset with genotype and tumour pathology information in mutation carriers collated through the CIMBA consortium.

The majority of the SNPs examined demonstrated stronger associations with ER-positive breast cancer for both *BRCA1*and *BRCA2*mutation carriers (Figure [2](#F2){ref-type="fig"}). Only rs2046210 on 6q25.1 exhibited stronger evidence for ER-negative disease. Among *BRCA1*mutation carriers, the most marked difference was for SNP rs2981582 in *FGFR2*, which was strongly associated with ER-positive breast cancer and exhibited no evidence of an association with ER-negative breast cancer (*P*= 6.5 × 10^-6^). Previous analyses of this polymorphism in mutation carriers failed to find an association with the overall risk of breast cancer for *BRCA1*mutation carriers, but found an association with risk for *BRCA2*mutation carriers \[[@B29],[@B31]\]. Our results suggest that rs2981582 in *FGFR2*also modifies ER-positive breast cancer risk for *BRCA1*mutation carriers to a similar relative extent as in *BRCA2*mutation carriers and ER-positive disease in the general population \[[@B27],[@B32]\]. Similar patterns were observed for SNPs rs3803662 in *TOX3/TNRC9*and rs4973768 in *SLC4A7/NEK10*in which the associations were predominantly with ER-positive breast cancer for both *BRCA1*and *BRCA2*mutation carriers, in line with results from studies of breast cancer in the general population \[[@B18],[@B21],[@B27]\]. The HR estimates for ER-positive breast cancer in *BRCA1*and *BRCA2*mutation carriers for these SNPs were very similar.

![**Summary of per-allele HR estimates for ER-positive and ER-negative breast cancer for mutation carriers**. The patterns of per-allele HR estimates (taken from Tables 2 and 3) suggest that the breast cancer subtype specific associations are similar between *BRCA1*and *BRCA2*mutation carriers.](bcr3052-2){#F2}

Among the 12 SNPs investigated in this report, SNP rs2046210 at 6q25.1 exhibited the strongest association with the risk of breast cancer for *BRCA1*mutation carriers in previous analyses, and was not associated with risk for *BRCA2*mutation carriers \[[@B28]\]. The current results suggest that this was mainly driven by an association with ER-negative breast cancer risk. This observation is again consistent with the effects seen in population-based studies, in which the relative risk is higher for ER-negative than ER-positive disease \[[@B42],[@B43]\] (Alison Dunning, personal communication). There was some evidence that the 6q25.1 SNP is also associated with ER-negative disease cancer subtype in *BRCA2*mutation carriers, although the estimates for ER-negative breast cancer in *BRCA2*mutation carriers are imprecise due to the relatively small sample size. In addition to the 12 loci investigated in this report, a recently identified locus at 19p13 also appears to be predominantly associated with ER-negative breast cancer \[[@B44]\].

The patterns of association between the SNPs and PR tumour status were similar to those observed for ER, which is not surprising given that ER and PR expression are highly correlated. There were, however, two notable exceptions. The 2q35 SNP rs13387042 demonstrated significantly stronger associations with PR-positive than PR-negative breast cancer for both *BRCA1*and *BRCA2*mutation carriers (*P*= 0.034 and *P*= 0.0086, for PR-positive for *BRCA1*and *BRCA2*respectively), suggesting this SNP may be more relevant for *BRCA1*and *BRCA2*tumours expressing PR. However, a population-based study has found this SNP is also associated with PR-negative breast cancer \[[@B45]\]. Furthermore, the *RAD51L1*locus was associated with PR-positive breast cancer for *BRCA1*mutation carriers and the magnitude of the association was similar to that observed in the general population \[[@B23]\] (A.B. Spurdle, personal communication).

Previous studies demonstrated that SNPs, which are associated with ER-positive breast cancer in the general population, tend to be associated with the breast cancer risk for *BRCA2*mutation carriers and SNPs, which are associated with ER-negative breast cancer in the general population, tend to be associated with the breast cancer risk for *BRCA1*mutation carriers \[[@B27],[@B31],[@B44]-[@B46]\]. The current results demonstrate that despite lack of an association between a SNP and the overall breast cancer risk for *BRCA1*or *BRCA2*mutation carriers, residual associations exist with specific disease subtypes. Figure [2](#F2){ref-type="fig"} summarises the association patterns in *BRCA1*and *BRCA2*mutation carriers. The HR estimates for ER-positive and ER-negative breast cancer among *BRCA1*mutation carriers appear to be different (intraclass correlation coefficient (ICC) approximately 0), as are the HR estimates for ER-positive and ER-negative breast cancer among *BRCA2*mutation carriers (ICC = 0.13). On the other hand the HR estimates for ER-positive breast cancer among *BRCA1*and *BRCA2*mutation carriers appear to be more similar (ICC = 0.65). There is, however, little correlation in the HR estimates for ER-negative breast cancer among *BRCA1*and *BRCA2*mutation carriers (ICC = 0.05). However, SNP 6q25.1, which is mainly associated with ER-negative disease in *BRCA1*mutation carriers, is estimated to confer similar HRs for ER-negative breast cancer for both *BRCA1*and *BRCA2*mutation carriers. These associations are mainly in the same direction and of similar magnitude to those observed with breast cancer in the general population stratified by ER expression status. Taken together, these findings are consistent with a model in which these SNPs and *BRCA1*or *BRCA2*mutations combine multiplicatively on the risk for ER-positive or ER-negative breast cancer \[[@B47]\]. Hence, the apparent differences in the strength of the SNP associations by *BRCA1*and *BRCA2*mutation status can be explained once tumour subtype is taken into account.

The major strength of the current study is the large sample of *BRCA1*and *BRCA2*mutation carriers with SNP and tumour marker information. Despite the large sample size, ER and PR marker information was only available for approximately 30% of the mutation carriers that had been diagnosed with breast cancer. The sample sizes for tumour subtypes, while still large, were, therefore, much smaller than were available for analyses of breast cancer risk overall, particularly for ER-positive breast cancer in *BRCA1*carriers and ER-negative breast cancer in *BRCA2*carriers. However, by analysing the data using a retrospective cohort approach and analysing the associations with ER-positive and ER-negative disease simultaneously we were able to include all mutation carriers in the analysis, including affected individuals with missing ER status, thus maximizing the available information. Ongoing efforts by CIMBA aim to increase the proportion of mutation carriers diagnosed with breast cancer who also have available tumour pathology information. This will enable us to assess the associations with breast cancer subtypes with greater precision.

The majority of the mutation carriers in CIMBA are identified through clinical genetics centers and, therefore, the source of information or definition of tumour marker status could vary across studies. This heterogeneity in classification may attenuate some of the differences by tumour type. For example, most commonly, a cut-off of 10% of cells staining was taken to denote positivity for ER and PR by the centers without further information on intensity or proportion of positive tumour nuclei and this was used for all our analyses; however, in centers that use the Allred score, a value of \> 2 denoted positivity, which may reflect as few as 1% of cells staining. In fact, recent recommendations suggest that ER and PgR assays be considered positive, for therapeutic purposes, if there are at least 1% positive tumour nuclei \[[@B48]\], but these data were not available for the majority of carriers in our samples to enable reclassification. It has been shown, however, that ER is almost always diffusely positive or completely negative (that is, it shows a bimodal staining pattern) with few cases falling between these extremes \[[@B49]\]. Given the small number of tumours likely to fall into the1 to 9% of cells staining category, the impact of changing the cutoff to 1% on our results would be limited. Furthermore, there was no evidence of variation in the distributions of ER or PR status across the studies separately for *BRCA1*and *BRCA2*tumours (Mavaddat N, Antoniou AC, personal communication, manuscript in preparation) and all analyses were stratified by country. Finally, the clear differences observed for some SNPs (most notably for *FGFR2*rs2981582, where the association was limited to ER-positive disease) suggest that the effect of misclassification in tumour subtype on the SNP associations is likely to have been small.

*BRCA1*and *BRCA2*tumours have also been found to differ in terms of other tumour characteristics compared to breast cancers in the general population. For example, tumours in mutation carriers are more likely to be of higher grade in comparison to breast cancers in the general population. The distribution of grade has been found to vary between ER-positive and ER-negative tumours in both *BRCA1*and *BRCA2*mutation carriers (Mavaddat N, Antoniou AC, personal communication, manuscript in preparation). Although the number of carriers with information on grade, ER status and SNPs was too small to permit combined analysis, our results are unlikely to have been influenced after adjusting for tumour grade. Case-only analysis to test for differences in associations between the SNPs and tumour grade (using ordinal logistic regression) revealed no significant associations between any of the SNPs and grade for both *BRCA1*and *BRCA2*mutation carriers (*P*\> 0.05 for all tests, results not shown).

The analysis was performed within a retrospective cohort approach, by extending the retrospective likelihood approach described previously \[[@B36]\] to model the simultaneous effects on different breast cancer subtypes defined by ER/PR. Under this approach the associations were estimated simultaneously for the tumour subtypes under investigation. This method depends on the assumption that ascertainment of mutation carriers does not depend on tumour subtypes. This is a reasonable assumption since more than 90% of mutation carriers in our sample were recruited prior to 2007, when it was uncommon to use tumour pathology in selecting individuals for *BRCA1*and *BRCA2*mutation screening. Furthermore, the results were virtually identical in a case only, logistic regression analysis for testing for differences in the associations with tumour subtypes which included only individuals with known tumour characteristics (results not shown).

The average risks of developing ER-positive and ER-negative breast cancer in both *BRCA1*and *BRCA2*mutation carriers are substantially higher compared to the general population \[[@B38]\]. Therefore, in combination, these SNPs lead to much bigger differences in the absolute risk of developing the disease subtypes between the extremes of the combined SNP genotype distributions \[[@B50]\]. Based on the SNP profiles investigated in this report, the absolute risk difference between mutation carriers at the top 5% of the risk distribution compared to the bottom 5% is much greater for ER-positive breast cancer than for ER-negative breast cancer for both *BRCA1*and *BRCA2*(Figure [1](#F1){ref-type="fig"}). Recent GWAS have identified several other common breast cancer susceptibility variants which have not been investigated in *BRCA1*and *BRCA2*mutation carriers yet \[[@B24],[@B51]\]. Moreover, ongoing GWAS in *BRCA1*and *BRCA2*mutation carriers \[[@B44],[@B52]\] may also identify further modifiers of breast cancer risk for mutation carriers. It will be important to investigate the associations of these variants with different disease subtypes in *BRCA1*and *BRCA2*mutation carriers. Currently, it is unusual for the risks of different disease subtypes to be taken into account in the genetic counseling process. However, as more risk modifying variants are identified in the future, provided these have different associations with different disease subtypes in mutation carriers and confer relative risks which are greater (or smaller) than 1, having precise breast cancer subtype risks may be useful for the planning of the clinical management of both *BRCA1*and *BRCA2*mutation carriers. For example, knowing that a female *BRCA1*mutation carrier was primarily at risk of ER-positive breast cancer based on her associated SNP profile (rather than ER-negative breast cancer, as is the case for the majority of cases) might potentially influence the choice of clinical management by screening, chemoprevention or prophylactic surgery.

Conclusions
===========

In summary, in this report we investigated the associations of common breast cancer polymorphisms with ER and PR status. Our results indicate there are differential associations between these SNPs and the risk of developing ER-positive or ER-negative breast cancer in *BRCA1*and *BRCA2*mutation carriers that mirror similar differences seen in the general population. The findings add to our understanding of the biology of tumour development in mutation carriers and as more risk variants are identified in the future they may improve clinical management of these individuals.
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